- €75.15m
- €372.31m
- €786.44m
Brief: Guerbet H1 EBITDA Up At 61.6 Million Euros
Brief: Guerbet Signs New Agreement With IBM Watson Health On AI Solution
Brief: Guerbet H1 Revenue Up At EUR 400.6 Million
Brief: Guerbet Obtains CE Marking For SeQure And DraKon
French and Benelux stocks-Factors to watch
Brief: Guerbet Q1 Revenue Up At 195.4 Million Euros At Constant Exchange Rates
Brief: Guerbet: Transition From Temporary Importation To Regular Supply For Lipiodol Injection
Europe Research Roundup: Essity, Ferguson, Metro Bank
Brief: Guerbet Sees Moderate Growth In Sales In 2019
Brief: Guerbet Says OptiVantage Multi-Use Injector Is Now CE-Marked
Brief: Guerbet 9-Month Revenue Down At 581.4 Million Euros
Brief: Guerbet Sees 2018 Sales Slightly Exceeding 2017 Sales
Brief: Guerbet H1 Net Income Down At 22.4 Million Euros
Brief: New Indication Approved For Guerbet’s Lipiodol Ultra Fluid
Brief: Guerbet H1 Revenue Down At 389.6 Million Euros
Brief: Guerbet And IBM Watson Health Signs Strategic Partnership For AI In Medical Imaging
Brief: Guerbet Announces Acquisition Of A New Microsphere Technology
Brief: Guerbet Expects 2018 Revenue In-Line With 2017
Brief: Guerbet Q1 Revenue Stable At 196.5 Million Euros